Daxor【DXR】銘柄情報

Daxor Corporation (DXR) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

11.0866

( 3.32% )

買値

10.01

売値

11.07

出来高

1,006

10.26 日の範囲 11.09

8.2887 52 週間の範囲 15.00

時価総額

64.604M

前日終値

10.73

始値

10.71

時刻

10.845

最終取引時間

財務取引量

US$ 10,863

VWAP

10.7983

平均取引量 (3 か月)

US$ 11,298

発行済株式数

5,827,225

配当利回り

PER

5.67

1 株当たり利益 (EPS)

1.81

歳入

26.69k

純利益

9.17M

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was for... Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh. 詳細を表示

セクター

Healthcare

業界

Medical Equipment & Supplies

ウェブサイト

www.daxor.com

本社

Oak Ridge, United States

設立

1971

Daxor Corporation is listed in the Healthcare sector of the ナスダック市場 with ticker DXR. The last closing price for Daxor was US$10.73. Over the last year, Daxor shares have traded in a share price range of US$ 8.2887 to US$ 15.00.

Daxor currently has 5,827,225 shares in issue. The market capitalisation of Daxor is US$64.60 million. Daxor has a price to earnings ratio (PE ratio) of 5.67.

Form DEF 14A - Other definitive proxy statements

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

New Technology Expands Daxor’s Diagnostic Capabilities to Enable Continuous, Remote Tracking of Blood Volume...

Form NT NPORT-P - EDGAR generated form type for a late filing of a Monthly Portfolio Investments Report on Form N-PORT (Public)

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.8966	8.79882237488	10.19	11.16	9.61	1538	10.12754746	CS
4	1.2066	12.2125506073	9.88	12.22	9.1	6747	10.11775212	CS
12	-0.2934	-2.57820738137	11.38	12.3114	8.56	8920	9.99568815	CS
26	-1.5634	-12.3588932806	12.65	15	8.56	7916	11.13467933	CS
52	2.4566	28.4658169177	8.63	15	8.2887	12424	10.8804574	CS
156	1.3366	13.7087179487	9.75	15	6.55	7739	9.90915992	CS
260	0.1166	1.06289881495	10.97	15	6.55	6856	10.06966026	CS

DXR - Frequently Asked Questions (FAQ)

What is the current Daxor Corporation share price?

The current share price of Daxor Corporation is US$ 11.0866

How many Daxor Corporation shares are in issue?

Daxor Corporation has 5,827,225 shares in issue

What is the market cap of Daxor Corporation?

The market capitalisation of Daxor Corporation is USD 64.6M

What is the 1 year trading range for Daxor Corporation share price?

Daxor Corporation has traded in the range of US$ 8.2887 to US$ 15.00 during the past year

What is the PE ratio of Daxor Corporation?

The price to earnings ratio of Daxor Corporation is 5.67

What is the cash to sales ratio of Daxor Corporation?

The cash to sales ratio of Daxor Corporation is 2.24k

What is the registered address of Daxor Corporation?

The registered address for Daxor Corporation is 109 Meco Lane, Oak Ridge, Tennessee, 37830

What is the Daxor Corporation website address?

The website address for Daxor Corporation is www.daxor.com

Which industry sector does Daxor Corporation operate in?

Daxor Corporation operates in the Medical Equipment & Supplies sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Daxor Corporation (DXR)

Daxor Corporation (DXR) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Daxor Corporation について

DXR 最新ニュース

Form DEF 14A - Other definitive proxy statements

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Form NT NPORT-P - EDGAR generated form type for a late filing of a Monthly Portfolio Investments Report on Form N-PORT (Public)

Form 40-8F-2/A - Application for deregistration [Rule O-2]: [Amend]

Form 40-17F2 - Certificate of accounting of securities in custody of management investment companies [Rule 17f-2]

Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis

Form 4 - Statement of changes in beneficial ownership of securities

Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center

Form N-CEN/A - Annual Report for Registered Investment Companies: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form DEF 14A - Other definitive proxy statements

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Form NT NPORT-P - EDGAR generated form type for a late filing of a Monthly Portfolio Investments Report on Form N-PORT (Public)

Form 40-8F-2/A - Application for deregistration [Rule O-2]: [Amend]

Form 40-17F2 - Certificate of accounting of securities in custody of management investment companies [Rule 17f-2]

Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis

Form 4 - Statement of changes in beneficial ownership of securities

Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center

Form N-CEN/A - Annual Report for Registered Investment Companies: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 40-17F2 - Certificate of accounting of securities in custody of management investment companies [Rule 17f-2]

Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026

DXR - Frequently Asked Questions (FAQ)

DXR 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する